4/7/2021 7:07:14 AM
Alkermes Enters Clinical Trial Collaboration And Supply Agreement With Merck
3/25/2021 7:07:27 AM
Alkermes Plans To Provide New Updates And Disclose New Programs In Neuroscience And Oncology Development Pipeline
3/11/2021 7:01:48 AM
Alkermes Announces FDA Grants Orphan Drug Designation For Nemvaleukin Alfa For Treatment Of Mucosal Melanoma
2/11/2021 7:02:04 AM
Alkermes Plc Q4 Loss Per Share $0.27; Non-GAAP EPS $0.10
1/14/2021 7:04:18 AM
Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion For Treatment Of MUD Published
1/6/2021 7:02:55 AM
Alkermes Names Blair Jackson COO And Iain Brown CFO
12/29/2020 7:02:03 AM
FDA Accepts Alkermes' Resubmission Of NDA For ALKS 3831; FDA Sets PDUFA Target Action Date Of June 1, 2021
12/10/2020 7:02:17 AM
Alkermes Announces Profitability Targets & Cost Structure Optimization Efforts